The 510(k) Process: Evaluating Substantial Equivalence in Premarket Notifications

Instructor: Ana Maria Saaibi
Product ID: 703688
  • Duration: 60 Min
Each 510(k) submission poses a new set of challenges and new variations, depending on the type of device, the risk level, and its history. Therefore, it is essential to have a strong understanding of the most up-to-date 510(k) submission requirements and how they relate to your device for the most efficient submission process. This course will elaborate device classification, overview the 510(k) program, and discuss FDA submissions.

recorded version

1x Person - Unlimited viewing for 6 Months
(For multiple locations contact Customer Care)
Recorded Link and Ref. material will be available in My CO Section
Last Recorded Date: Nov-2014

Training CD / USB Drive

One CD/USB is for usage in one location only.
(For multiple locations contact Customer Care)
CD/USB and Ref. material will be shipped within 15 business days

Customer Care

Fax: +1-650-362-2367


Read Frequently Asked Questions

Why Should You Attend:

The process of compiling and submitting a 510(k) for medical device companies, especially small companies, can be ambiguous. It requires considerable investment of time and resources. Toiling through this process can be overwhelming and also a constant struggle with bureaucratic hurdles. Understanding how this process works and the reasoning behind the FDA’s decision making process can not only save time and money, but also position the company in market advantage.

This webinar will give you a better understanding of FDA’s current position regarding the 510(k) process and provide you with the resources necessary to develop a better regulatory strategy. It will detail the process of demonstration of substantial equivalence, the 510(k) process, and also highlight best practices for premarket notification 510(k) submissions.

Areas Covered in the Webinar:

  • Device classification as it relates to 510(k)s
  • Device classification
  • Overview of 510(k) program
  • Content of a 510(k)
  • 510(k) submission process
  • 510(k) decisions

Who Will Benefit:

This webinar will provide valuable assistance to all personnel in:

  • Regulatory Affairs
  • Quality Assurance
  • Compliance
  • Research and Development
  • Quality Engineering
  • Risk Managers
  • Executive Management
  • Risk Management

Instructor Profile:

With a double major in mechanical engineering and mathematics and a master’s in biomedical engineering, Ana Maria Saaibi has more than 6 years of medical device experience in both product development and quality and regulatory affairs. She has lead device work for both the U.S. domestic market and international markets. She has experience in medical device regulatory submissions to the FDA (US), INVIMA (Colombia) and Notified Bodies for the CE Mark as well as the development of quality management systems compliant with ISO 13485:2003, FDA QSR and MDD. Ms. Saaibi is an ASQ (American Society of Quality) certified biomedical auditor since 2012 and a RABQSA auditor in training.

Topic Background:

To be cleared for market in the U.S., a new device must be found substantially equivalent (SE) to a predicate device according to the Federal Food, Drug, and Cosmetic Act (FDC Act). To be found SE, the new device must have the same intended use as the predicate and either the same technological characteristics as the predicate, or, if different technological characteristics exist, those differences cannot raise different questions of safety and effectiveness than those of the predicate device. The device must demonstrate that it is as safe and effective as the legally marketed device. This demonstration of substantial equivalence is commonly referred to as the 510(k) process.

The FDA released the new guidance for the 510(k) program and the substantial equivalence determination on July 28th of this year. FDA developed the document to provide guidance to the industry and FDA staff about current review practices for premarket notification 510(k) submissions. The intent of this guidance is to identify, explain, and clarify each of the critical decision points in the decision-making process FDA uses to determine substantial equivalence.

Follow us :

Refund Policy

Registrants may cancel up to two working days prior to the course start date and will receive a letter of credit to be used towards a future course up to one year from date of issuance. ComplianceOnline would process/provide refund if the Live Webinar has been cancelled. The attendee could choose between the recorded version of the webinar or refund for any cancelled webinar. Refunds will not be given to participants who do not show up for the webinar. On-Demand Recordings can be requested in exchange.

Webinar may be cancelled due to lack of enrolment or unavoidable factors. Registrants will be notified 24hours in advance if a cancellation occurs. Substitutions can happen any time.

If you have any concern about the content of the webinar and not satisfied please contact us at below email or by call mentioning your feedback for resolution of the matter.

We respect feedback/opinions of our customers which enables us to improve our products and services. To contact us please email call +1-888-717-2436 (Toll Free).

Product Reviews

This product hasn't received any reviews yet. Be the first to review this product! Write review

Best Sellers
You Recently Viewed